ERBB2 and breast cancer: According to reports, heregulin is excreted from intestinal cells and activates cancer cells in a paracrine manner.7, 22 Therefore, we evaluated the effect of triple combination therapy using a heregulin paracrine model with HER2‐positive breast cancer cell lines including BT‐474, MDA‐MB‐453, and HCC1419.